New AI-based tool helps clinicians understand and better predict adverse effects of COVID-19

The symptoms and side effects of Covid-19 are scattered across a diagnostic spectrum. Some patients are asymptomatic or experience a mild immune response, while others report significant long-term illnesses, lasting complications, or suffer fatal outcomes. Three researchers from the Georgia Institute of Technology and one from Emory University are trying to help clinicians sort through these factors and spectrum of patient outcomes by equipping healthcare professionals with a new "decision prioritization tool." The team's new artificial intelligence-based tool helps clinicians understand and better predict which adverse effects their Covid-19 patients could experience, based on comorbidities and current side effects -; and, in turn, also helps suggest specific Food and Drug Administration-approved (FDA) drugs that could help treat the disease and improve patient health outcomes. The researcher's latest findings are the focus of a new study published October 21 in Scientific Reports. The team's new methodology, or tool, is called MOATAI-VIR (Mode Of Action proteins & Targeted therapeutic discovery driven by Artificial Intelligence for VIRuses.